Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr. Thompson on the Future of Treatment in Multiple Myeloma

March 24th 2017

Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses the future of treatment in multiple myeloma.

Dr. Landgren on Using Daratumumab for Patients With Multiple Myeloma

March 23rd 2017

C. Ola Landgren, MD, PhD, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses using daratumumab (Darzalex) for the treatment of patients with multiple myeloma.

Dr. Lonial Discusses Recent Updates in Multiple Myeloma

March 9th 2017

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses updates in multiple myeloma.

Lonial Discusses Dramatic Progress in Multiple Myeloma

March 8th 2017

Sagar Lonial, MD, discusses recent advances that have revolutionized the treatment of patients with multiple myeloma.

Novel Study of Next-Generation BCMA-Targeted CAR-Modified T Cells for Multiple Myeloma Opens at MSK

March 6th 2017

Ola Landgren, MD, PhD, discusses a new clinical trial at Memorial Sloan Kettering examining a novel myeloma-directed CAR T-cell therapy developed by researchers at the cancer center.

Denosumab Effective in Delaying SREs in Myeloma

March 6th 2017

Denosumab (Xgeva) demonstrated noninferiority to zoledronic acid (Zometa) at delaying the time to the first skeletal-related event in patients with multiple myeloma, according to the full results of the phase III 482 study presented at the 16th International Myeloma Workshop in New Delhi.

Dr. Lonial on Advancements in the Treatment of Myeloma

March 2nd 2017

Sagar Lonial, MD, FACP, professor and chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, chief medical officer at Winship Cancer Institute of Emory University, discusses recent advancements in the field of multiple myeloma.

Carfilzomib Improves Survival in Relapsed Multiple Myeloma

March 1st 2017

Carfilzomib (Kyprolis) plus dexamethasone improved overall survival by 21% versus dexamethasone plus bortezomib (Velcade) in patients with relapsed or refractory multiple myeloma, according to findings from the phase III ENDEAVOR trial.

Outcomes Have Improved Over Time in Myeloma Patients Relapsing Early After ASCT

February 25th 2017

Rates of early relapse post-autologous stem cell transplant in patients with relapsing multiple myeloma have not changed over time, but post-relapse survival among early relapsers has improved for patients transplanted after 2005 and for those relapsing since 2008.

Carfilzomib Maintenance Improves Response Following Transplant in Relapsed Multiple Myeloma

February 25th 2017

According to data from a phase I/II clinical trial, carfilzomib can be safely combined with melphalan in a conditioning regimen prior to autologous hematopoietic cell transplantation in patients with relapsed multiple myeloma.

Daratumumab Triplets Recommended for EU Approval in Myeloma

February 25th 2017

The EMA’s Committee for Medicinal Products for Human Use has recommended approval of daratumumab (Darzalex) in combination with lenalidomide (Revlimid) and dexamethasone or bortezomib (Velcade) and dexamethasone for patients with relapsed multiple myeloma following at least 1 prior therapy.

EC Approves Maintenance Lenalidomide for Myeloma

February 24th 2017

The European Commission has expanded the indication for lenalidomide (Revlimid) to include use as a maintenance therapy for patients with multiple myeloma following autologous hematopoietic stem cell transplant.

FDA Approves Maintenance Lenalidomide for Myeloma

February 23rd 2017

The FDA has approved lenalidomide (Revlimid) as a maintenance therapy for patients with multiple myeloma following autologous hematopoietic stem cell transplant.

Dr. Smith on Immunotherapy Potential in Multiple Myeloma

February 20th 2017

Eric Smith, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the potential of immunotherapy in the treatment landscape of multiple myeloma.

Dr. Kelly on BT062 Combination With Lenalidomide for R/R Myeloma

February 20th 2017

Kevin R. Kelly, MD, PhD, associate professor of Medicine, Keck School of Medicine, discusses indatuximab ravtansine (BT062) in combination with lenalidomide (Revlimid) in patients with relapsed or refractory multiple myeloma.

Expert Highlights Immunotherapy Advances in Myeloma

February 20th 2017

Eric Smith, MD, PhD, discusses recently reported phase II data combining elotuzumab (Empliciti) with lenalidomide (Revlimid) and dexamethasone.

Dr. Thompson on Advancements in Treatments of Multiple Myeloma

February 16th 2017

Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses advancements of treatments for patients with multiple myeloma.

Dr. Kelly on Phase Ib Study of Reolysin Plus Bortezomib in Multiple Myeloma

February 11th 2017

Kevin R. Kelly, MD, PhD, associate professor of Medicine, Keck School of Medicine discusses reolysin plus bortezomib (Velcade) in paitents with multiple myeloma.

Dr. Kumar on Next Steps for Venetoclax in Multiple Myeloma

February 10th 2017

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the next steps for venetoclax (Venclexta) in the treatment of patients with multiple myeloma.

Dr. Jackson on the Toxicity Profile of Lenalidomide Maintenance in Myeloma

February 9th 2017

Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses the toxicity profile of lenalidomide maintenance therapy in the treatment of patients with multiple myeloma.